Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ranibizumab + bromfenac
- Development stage
- Phase 2
- Lead developer
- Genentech
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravitreal, Topical
01
Overview
Ranibizumab + bromfenac is a combination therapy used in ophthalmology, particularly for the treatment of ocular diseases characterized by abnormal blood vessel growth and inflammation, such as neovascular (wet) age-related macular degeneration and diabetic macular edema. Ranibizumab is a recombinant humanized monoclonal antibody fragment that binds to vascular endothelial growth factor A (VEGF-A), inhibiting its interaction with VEGF receptors on endothelial cells, thereby reducing angiogenesis and vascular leakage. Bromfenac is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase 1 and 2 enzymes, blocking prostaglandin synthesis to reduce ocular inflammation. Clinical studies suggest that adjunctive use of topical bromfenac with intravitreal ranibizumab may reduce the frequency of required injections and enhance anatomical outcomes in patients[1][4][5][6].
- Brand names
- Lucentis (for ranibizumab)
- Other names
- Xibrom + Lucentis
02
Targets
PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on ranibizumab + bromfenac.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ranibizumab + bromfenac.